An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors

Biomarkers

Volumn 15, Issue 1, 2010, Pages 31-38

  Dakappagari, Naveen ^a   Neely, Laura ^a   Tangri, Shabnam ^a   Lundgren, Karen ^a   Hipolito, Lori ^a   Estrellado, Annalee ^a   Burrows, Francis ^a   Zhang, Hong ^a  

^a BIOGEN   (United States)

Author keywords

Cancer; Hsp70; Hsp90 inhibitor; SCLC; Serum biomarker

Indexed keywords

BIIB 021; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90 INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER THERAPY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; LUNG CANCER; MELANOMA; MOUSE; MYELOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; PROTEIN SECRETION; WESTERN BLOTTING;

ADENINE; ANIMALS; CELL LINE, TUMOR; CHEMILUMINESCENT MEASUREMENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL; PHARMACOKINETICS; PYRIDINES; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 75749122202     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547500903261347     Document Type: Article

References (24)

1. Bagatell Hunger R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock J, A, SP, Narendran Rocha A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM. (2007). Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13:1783-1788
2. Banerji U, Affolter A, Judson I, Marais R, Workman P. (2008). BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 7:737-739
3. Banerji U, O'donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I. (2005). Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152-4161 (Pubitemid 46211321)
4. Basso AD, Solit DB, Munster PN, Rosen N. (2002). Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21: 1159-1166
5. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit DB. (2008). SNX2112 a synthetic heat shock protein 90 inhibitor has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14:240-248
6. Chang CL, Tsai YC, He L, Wu TC, Hung CF. (2007). Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70. Cancer Res 67:10047-10057
7. Da Dias S, Friedlos D F, Light Y, Springer C, Workman P, Marais R. (2005). Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65:10686-10691
8. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, Rosen N. (2006). V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 103:57-62.
9. Mambula SS, Calderwood SK. (2006). Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol 177:7849-7857
10. Massa C, Guiducci C, Arioli I, Parenza M, Colombo MP, Melani C. (2004). Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res 64:1502-1508
11. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C. (2006). A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 12:6087-6093
12. Ramanathan RK, Trump L, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ. (2005). Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG NSC 330507), a novel inhibitor of heat shock protein 90 in patients with refractory advanced cancers. Clin Cancer Res 11:3385-3391
13. Seiwert TY, Tretiakova M, Ma PC, Khaleque MA, Husain AN, Ladanyi A, Chen LB, Bharti A, Salgia R. (2005). Heat shock protein (HSP). Overexpression in lung cancer and potential as a therapeutic target. Proc Am Assoc Cancer Res 46:2387.
14. Singh-Jasuja H, Hilf N, Scherer HU, Arnold-Schild D, Rammensee HG, Toes RE, Schild H. (2000). The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells. Cell Stress Chaperones 5:462-470 (Pubitemid 32057499)
15. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. (2006). Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 47:793-796
16. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, Delacruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI. (2007). Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13:1775-1782 (Pubitemid 46952945)
17. Srivastava PK, Udono H, Blachere NE, Li Z. (1994). Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39:93-98
18. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. (1997). Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117-120
19. Theriault JR, Adachi H, Calderwood SK. (2006). Role of scavenger receptors in the binding and internalization of heat shock protein 70. J Immunol 177:8604-8611
20. Wang XY, Arnouk H, Chen X, Kazim L, Repasky EA, Subjeck JR. (2006). Extracellular targeting of endoplasmic reticulum chaperone glucose-regulated protein 170 enhances tumor immunity to a poorly immunogenic melanoma. J Immunol 177:1543-1551
21. Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames M, Adamson PC. (2007). A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res 13:1789-1793 (Pubitemid 46952947)
22. Workman P. (2003). Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2:131-138
23. Workman P, Burrows F, Neckers L, Rosen N. (2007). Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113:202-216
24. Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K, Burrows F. (2006). Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 5:1256-1264